Adrenergic regulation of cell volume-regulated chloride current (I Cl.vol ) is species-dependent. The present study investigates the mechanism underlying adrenergic regulation of I Cl.vol in human atrial myocytes.
KEY RESULTS
I Cl.vol was augmented by noradrenaline (1 μM) during cell swelling in 0.6 T but not under isosmotic (1 T) conditions. Upregulation of I Cl.vol in 0.6 T was blocked by the β-adrenoceptor antagonist propranolol (2 μM), but not by the α 1 -adrenoceptor antagonist prazosin (2 μM). This β-adrenergic response involved cAMP but was independent of PKA; the protein kinase inhibitor H-89 (2 μM) or PKI (10 μM in pipette solution) failed to prevent I Cl.vol up-regulation by noradrenaline. Moreover, the PI3K/PKB inhibitor LY294002 (50 μM) and the PKG inhibitor KT5823 (10 μM) did not affect noradrenaline-induced increases in I Cl.vol . Interestingly, the exchange protein directly activated by cAMP (Epac) agonist 8-pCPT-2 0 -O-Me-cAMP (50 μM) also up-regulated I Cl.
vol , and the noradrenaline-induced increase of I Cl.vol in 0.6 T was reversed or prevented by the Epac inhibitor ESI-09 (10 μM).
CONCLUSION AND IMPLICATIONS
These data show that I Cl.vol evoked by cell swelling of human atrial myocytes is up-regulated by noradrenaline via a PKAindependent cAMP/Epac pathway in human atrial myocytes. cAMP/Epac-induced I Cl.vol is expected to shorten action potential duration during human atrial myocytes swelling and may be involved in abnormal cardiac electrical activity during cardiac pathologies that evoke β-adrenoceptor signalling.
Abbreviations 0.6 T, 0.6-fold isosmotic; Epac, exchange protein activated by cAMP; ESI-09, 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chlorophenyl)-hydrazono]-3-oxo-propionitrile; I Cl.vol , volume-regulated chloride current; DIDS, 4,4 0 -diisothiocyanostilbene-2,2 0 -disulfonic acid; PTKs, protein tyrosine kinases; 8-pCPT-2 0 -O-Me-cAMP, 8-(4-chlorophenylthio)-2 0 -O-methyladenosine-3 0 , 5 0 -cyclic monophosphate
Introduction
The volume-regulated chloride current (I Cl.vol ; also called I Cl.swell or VRAC) in mammalian cardiac myocytes is activated by cell swelling (Li et al., 1996b) and/or membrane deformation (Du and Sorota, 1997b; Browe and Baumgarten, 2003) , shortens action potential duration (Vandenberg et al., 1997) and depolarizes resting membrane potential (Du and Sorota, 1997a) . Therefore, I Cl.vol may play a role in cardiac electrophysiology and arrhythmogenesis in situ (Hiraoka et al., 1998) . Cardiac I Cl.vol is regulated by several signalling pathways (Sorota, 1999; Hume et al., 2000; Baumgarten and Clemo, 2003) , including protein tyrosine kinases (PTKs) (Du et al., 2004; Ren and Baumgarten, 2005; Browe and Baumgarten, 2006) and adrenoceptor-mediated protein kinases, such as PKA and PKC) Baumgarten and Clemo, 2003) , and reactive oxygen species (Browe and Baumgarten, 2004; Ren et al., 2008; Deng et al., 2010) . Adrenoceptor-mediated regulation of I Cl.vol is inconsistent in reports from groups studying cardiac myocytes from different species under various experimental conditions. The α 1 -adrenoceptor agonist phenylephrine and noradrenaline were reported to inhibit I Cl.vol by activating PKC in rabbit atrial myocytes (Duan et al., 1995) . However, a recent report demonstrated that I Cl.vol is increased by phenylephrine via activating PKC in human atrial myocytes (Li and Du, 2015) . Regulation of cardiac I Cl.vol by β-adrenoceptormediated cAMP/PKA is also inconsistent. I Cl.vol is inhibited by the cAMP activator forskolin in cultured chick cardiac myocytes (Hall et al., 1995) but is stimulated by the β-adrenoceptor agonist adrenaline or forskolin in canine atrial myocytes (Sorota, 1992) and in human atrial and ventricular myocytes (Oz and Sorota, 1995) . Blockade of protein kinases failed to modulate I Cl.vol in canine ventricular myocytes (Tseng, 1992) or in native guinea pig cardiac myocytes; recombinant gpClC3 channels (I Cl.vol ) expressed in NIH 3 T3 cells are inhibited by cAMP (Nagasaki et al., 2000) . The present study was designed to characterize how I Cl.vol is regulated by the sympathetic neurotransmitter noradrenaline in human atrial myocytes. The results demonstrated for the first time that noradrenaline up-regulates I Cl.vol during swelling by activating the cAMP-dependent exchange protein activated by cAMP (Epac) pathway.
Methods

Human atrial myocyte isolation
The protocol for tissue collection was approved by the Ethics Committee of the University of Hong Kong (UW-10-174) with the patients' consent. Human right atrial specimens were obtained from patients in sinus rhythm undergoing coronary artery bypass or valve replacement surgery (see Supporting Information Table S1 ). All patients were free from supraventricular tachyarrythmias, and the atria were grossly normal at the time of surgery. Human atrial myocytes were enzymically dissociated with the procedure described previously (Li et al., 2008; Xiao et al., 2017 ; T, times-isosmotic) solution was prepared by reducing NaCl of Tyrode's solution from 140 to 80 mM, and isosmotic 1 T (~300 mosmol·L ). The high K + storage medium contained 10 KCl, 120 K-glutamate, 10 KH 2 PO 4 , 1.8 MgSO 4 , 10 taurine, 10 HEPES, 0.5 EGTA, 20 glucose, 10 mannitol, pH adjusted to 7.3 with KOH. All experiments were done at room temperature, 21-22°C. Stock solutions of 8-pCPT-2 0 -O-Me-cAMP were aliquoted and stored at À20°C. DIDS, H-89, LY294002, KT58023 and ESI-09 were prepared in DMSO, aliquoted and stored at À20°C. Noradrenaline and isoprenaline stocks were freshly prepared in 1 mM ascorbic acid solution. All stock solutions were dissolved in extracellular bath solution immediately before use.
Data acquisition
A small aliquot of the solution containing the isolated cells was placed in an open perfusion chamber (1 mL) mounted on the stage of an inverted microscope (Leica DM IL, Wetzlar, Germany). Myocytes were allowed to adhere to the bottom of the chamber for 5-10 min and were then superfused at 2-3 mL·min À1 with isosmotic 1.0 T, hyposmotic 0.6 T or hyperosmotic 1.4 T Tyrode's solution. To ensure prompt and complete reversal of 0.6 T-induced swelling under patch clamp conditions, cells were exposed to 1.4 T rather than 1.0 T solution. Whole-cell currents were recorded as described previously (Du et al., 2004; Jie et al., 2017) using an EPC-9 amplifier and Pulse software (Heka, Lambrecht, Germany) , and signals were low-pass filtered (2 kHz) before 5 kHz digitization. Pipette resistance was 2-3 MΩ in bath solution. Series resistance (Rs, 3-8 MΩ) was compensated (60-80%) after membrane rupture, and a 3 M KCl-agar bridge was used as a reference electrode. The calculated junction potential (+12 mV) between pipette solution and bath solution was not corrected. Current was elicited with 3 s voltage ramps from À100 to +70 mV from a holding potential of À40 mV (10 s interval) and/or with 300 ms step voltage steps to À100 to +60 mV from À40 mV (10 mV increment). Data obtained from cells with increasing leak current and/or unstable Rs were not included for analysis.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . Results are presented as mean ± SEM. Paired or unpaired Student's t-tests were used as appropriate to evaluate differences between two groups, and one-way ANOVA followed by the Newman-Keuls test was used for comparisons between multiple groups for current densities at +60 mV. Values of P less than 0.05 were considered to indicate statistical significance.
Materials
8-pCPT-2
0 -O-Me-cAMP was purchased from Biolog Life Science Institute (Bremen, Germany). All other compounds were obtained from Sigma-Aldrich.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c,d) 
Results
Noradrenaline up-regulated I Cl.vol in human atrial myocytes Figure 1A illustrates the time course of swelling-induced changes in membrane current at +70 and À100 mV in a human atrial myocyte when bath solution was switched from isosmotic 1 T to hyposmotic 0.6 T solution; currents were elicited with a voltage ramp from À100 to +70 mV from a holding potential of À40 mV. Membrane current in 0.6 T outwardly rectified and gradually increased to a steady state level after about 30 min. The sympathetic neurotransmitter noradrenaline (1 μM) induced an additional increase of outwardly rectifying membrane current under 0.6 T conditions that reached to a steady state in 5 min, and the current in 0.6 T plus noradrenaline fully returned to control levels after exposure to hyperosmotic 1.4 T solution; 1.4 T rather than 1 T solution was utilized to ensure full and prompt reversal of cell swelling under patch clamp conditions. Similar results were obtained with 300 ms step voltage steps in five cells ( Figure 1B ). Currents at +60 mV in 1 T, 0.6 T, 0.6 T plus noradrenaline and 1.4 T plus noradrenaline were 1.1 ± 0.3 pA/pF, 9.8 ± 1.1 pA/pF (significantly different from 1 T), 13.1 ± 1.3 pA/pF (significantly different from 0.6 T alone) and 1.2 ± 0.4 pA/pF (significantly different from 0.6 T or 0.6 T plus noradrenaline; not significantly different from 1 T).
In contrast to its effect during cell swelling, 1 μM noradrenaline failed to elicit current under isosmotic 1 T conditions (see Supporting Information Figure S1 ) (n = 5, 1.2 ± 0.3 pA/pF in control ; 1.3 ± 0.2 pA/pF with noradrenaline).
The swelling-activated current in human atrial myocytes is I Cl.vol , as described previously (Li et al., 1996b) and can be confirmed by the application of the I Cl.vol blocker DIDS (Sorota, 1999; Hume et al., 2000; Du et al., 2004) . Figure 1C displays families of currents in 1 T, 0.6 T (30 min), 0.6 T with 1 μM noradrenaline for 5 min and after adding 300 μM DIDS for 12 min. DIDS inhibited almost all of the current induced by 0.6 T and noradrenaline application. Figure 1D shows the current-voltage (I-V) relationships (n = 6) in control (1.0 T), after cell swelling (0.6 T), and in 0.6 T plus 1 μM noradrenaline. Noradrenaline significantly increased 0.6 T-induced current, and 300 μM DIDS almost fully inhibited the 0.6 T-and noradrenaline-induced currents.
In addition to fully suppressing currents elicited by cell swelling and by noradrenaline, DIDS also prevented current activation by cell swelling. Exposing human atrial myocytes to 300 μM DIDS during osmotic swelling prevents membrane conductance increased by 0.6 T or 0.6 T plus 1 μM noradrenaline (n = 5; see Supporting Information Figure S2 ). These results further support the notion that the current induced by cell swelling and additional application of noradrenaline is I Cl.vol in human atrial myocytes.
Effects of α-and β-adrenoceptor antagonists on stimulation of I Cl.vol by noradrenaline in human atrial myocytes
To determine whether noradrenaline-augmented I Cl.vol was due to α 1 -adrenoceptor activation, as observed with a high concentration of phenylephrine (Li and Du, 2015) , the α 1 -adrenoceptor antagonist prazosin (2 μM) was applied during cell swelling in 0.6 T solution. Figure 2A shows the time course of I Cl.vol recorded with a ramp protocol (as in Figure 1A ). Including prazosin in 0.6 T did not prevent augmentation of I Cl.vol by 1 μM noradrenaline. The currents activated by cell swelling and noradrenaline application were fully inhibited by 1.4 T. Similar results were observed with voltage step protocol in six cells ( Figure 2B ). At +60 mV, currents were 1.6 ± 0.4 pA/pF in 1 T, increased to 11.3 ± 0.4 pA/pF in 0.6 T plus prazosin (P < 0.05), were further increased by adding noradrenaline to 14.8 ± 1.7 pA/pF (P < 0.05 vs. 0.6 T plus prazosin) and were fully suppressed in 1.4 T with prazosin plus noradrenaline (P = NS vs. 1 T). The 0.6 T-induced currents with and without prazosin also were not significantly different (P = NS, Figure 1B vs. Figure 2B ). These results suggest that augmentation of I Cl.vol by noradrenaline is not mediated by α 1 -adrenoceptor activation.
To investigate whether the I Cl.vol increase by noradrenaline (1 μM) is mediated by β-adrenoceptor activation, the β-adrenoceptor antagonist propranolol (2 μM) was applied during cell swelling in 0.6 T. The time course of I Cl.vol recorded with a ramp protocol ( Figure 2C ) shows that noradrenaline failed to stimulate I Cl.vol after β-adrenoceptor block. Similar results were observed with voltage steps in six cells ( Figure 2D ), and Figure 2E displays the I-V relationships. At +60 mV, current increased in 0.6 T plus propranolol, compared with the 1T value, but adding noradrenaline failed to further augment the current and, similarly, noradrenaline failed to up-regulate I Cl.vol at testing potentials of À100 to +60 mV. These results indicate that the noradrenalineinduced augmentation of I Cl.vol is mediated by β-adrenoceptor activation.
Activation of β-adrenoceptors stimulates adenylate cyclase, increases cAMP production, and in turn, activates PKA, which phosphorylates downstream target proteins. We therefore determined whether the noradrenaline-induced increase of I Cl.vol is related to the activation of cAMP and/or PKA. Effects of the PKA inhibitor H-89 on cAMP activation-induced increase of I Cl.vol Figure 3 illustrates the effects of the PKA inhibitor H-89 on I Cl.vol augmentation by noradrenaline, the selective β-adrenoceptor agonist isoprenaline, and the cAMP activator forskolin. Pretreatment with 2 μM H-89 failed to prevent up- regulation of I Cl.vol by 1 μM noradrenaline ( Figure 3A) , 1 μM isoprenaline ( Figure 3C ) or 5 μM forskolin ( Figure 3E ). In the presence of H-89 in 0.6 T, I Cl.vol (+60 mV) was increased by noradrenaline ( Figure 3B , n = 7), by isoprenaline ( Figure 3D , n = 6) and by forskolin ( Figure 3F , n = 6). In addition, 10 μM PKI, a PKA inhibitor (Li et al., 1996a) , included in the pipette solution did not prevent the up-regulation of I Cl.vol by 1 μM noradrenaline ( Figure 3G, 3H) . These results indicate that augmentation of I Cl.vol in 0.6 T occurred in response to cAMP, but did not require activation of PKA.
Effects of PI3K and PKG inhibitors on noradrenaline-induced augmentation of I Cl.vol An earlier study showed that cAMP directly activates cardiac pacemaker channels (DiFrancesco and Tortora, 1991), and therefore, the possibility that cAMP binding might activate the channel studied here cannot be ruled out. In addition, cAMP regulates TRPC6 channels by activating PI3K then PKB-MEK-ERK1/2 in glomerular mesangial cells (Shen et al., 2011) . Further, cAMP stimulates BK Ca channels in rat pulmonary arterial smooth muscle cells via cGMPdependent protein kinase (PKG) (Barman et al., 2003) . We therefore determined whether these protein kinases are involved in cAMP-induced augmentation of I Cl.vol . Figure 4 shows the effects of the PI3K inhibitor LY294002 and the PKG inhibitor KT5823 on the stimulation of I Cl.vol by noradrenaline. LY294002 (50 μM; Figure 4A , 4B) and KT5823 (10 μM; Figure 4C , 4D) failed to prevent the noradrenaline-induced I Cl.vol increase. These results suggest that the augmentation of I Cl.vol by noradrenaline does not require activating PI3K or PKG in human atrial myocytes. However, inhibition of PI3K suppresses I Cl.vol in rabbit cardiac myocytes (Browe and Baumgarten, 2006; Ren et al., 2008; Deng et al., 2010) , which may be related to the species studied.
Increase of I Cl.vol by noradrenaline is mediated by cAMP/Epacs
Earlier studies showed that cAMP targets Epacs in a PKAindependent manner (de Rooij et al., 1998; Kawasaki et al., 1998) . Epacs are believed to be cAMP sensor proteins that play important roles in cardiovascular physiology and pathophysiology (Bos, 2006; Fujita et al., 2017) . We therefore determined whether activation of Epacs could increase I Cl.vol using the cAMP analogue 8-pCPT-2-O-Me-cAMP, which selectively activates Epacs but not PKA (Enserink et al., 2002; Gloerich and Bos, 2010) . Figure 5A shows the time course of swellinginduced changes in membrane current recorded with when bath solution was switched from 1 T to 0.6 T solution. Hyposmotic 0.6 T exposure gradually increased the membrane conductance to a steady-state level. As previously shown with noradrenaline, the Epac activator 8-pCPT-2-OMe-cAMP (50 μM) promptly elicited an additional increase of membrane current in 0.6 T that rapidly reached a steady state, and the 8-pCPT-2-O-Me-cAMP-induced current in 0.6 T was fully reversed to control levels by hyperosmotic 1.4 T solution. Similar results were obtained by applying voltage steps in six cells ( Figure 5B ). Figure 5C illustrates the I-V relationships in 1.0 T, 0.6 T and 0.6 T plus 50 μM 8-pCPT-2-O-MecAMP. 8-pCPT-2-O-Me-cAMP significantly augmented I Cl.vol in human atrial myocytes. In contrast, 50 μM 8-pCPT-2-OMe-cAMP did not affect membrane conductance under 1 T conditions (see Supporting Information Figure S3 ). Thus, this cAMP-dependent Epac activator fully mimicked the results obtained with noradrenaline, isoprenaline and forskolin, which suggests these agents may up-regulate I Cl.vol by activating Epacs.
If noradrenaline-induced increase of I Cl.vol is mediated by activating cAMP/Epacs, Epac inhibitor should reverse or prevent the effect. The effect of the selective Epacs inhibitor ESI-09 (Almahariq et al., 2013) on noradrenaline-induced augmentation of I Cl.vol was tested after application of noradrenaline ( Figure 6A, B) . ESI-09 (10 μM) reversed upregulation of I Cl.vol by 1 μM noradrenaline in 0.6 T.
In another set of experiments, 10 μM ESI-09 was used to treat the cells during 0.6 T exposure and noradrenaline application ( Figure 6C, D) , and I Cl.vol activation by noradrenaline was fully prevented. These results confirm that the noradrenaline-induced increase of I Cl.vol in hypotonic solution is mediated through activation of cAMP/Epacs.
Discussion
In the present study, we demonstrated that the sympathetic neurotransmitter noradrenaline augmented the swellingactivated membrane conductance in human atrial myocytes exposed to 0.6 T hypotonic solution, and the current in 0.6 T and noradrenaline was reversed by 1.4 T. Based on its volume dependence, outward rectification, reversal near E Cl and inhibition by DIDS, the current is the cell swellingactivated chloride current I Cl.vol . The up-regulation of I Cl.vol by noradrenaline relies on β-adrenoceptor activation; it was blocked by propranolol and reproduced by isoprenaline. On the other hand, block of α 1 -adrenoceptors was ineffective. Although the response to β-adrenoceptor activation was mimicked by the elevation of cAMP with forskolin, the augmentation of I Cl.vol was PKA-independent and not suppressed by a PKA inhibitor. Rather, PKA-independent and cAMP-dependent up-regulation of I Cl.vol by noradrenaline during swelling was due to activation of Epacs; the response to noradrenaline was reproduced by a selective Epac activator, 8-pCPT-2-O-Me-cAMP, and was suppressed by the Epac inhibitor ESI-09.
It is generally believed that cardiac I Cl.vol is regulated by multiple signalling pathways (Sorota, 1999; Hume et al., 2000; Baumgarten and Clemo, 2003; Baumgarten et al., 2005) , for example, PTKs (Du et al., 2004; Ren and Baumgarten, 2005; Browe and Baumgarten, 2006) , adrenergic PKA and PKC Baumgarten and Clemo, 2003) . However, the adrenoceptor-mediated regulation (increase or decrease) of cardiac I Cl.vol is clearly speciesdependent. In rabbit atrial myocytes, the α 1 -adrenoceptor agonist phenylephrine and noradrenaline inhibited I Cl.vol activated by hypotonic exposure, the response was countered by the α 1 -adrenoceptor antagonist prazosin or PKC inhibition, and PKC activation also inhibited the current (Duan et al., 1995) . Nonetheless, PKC stimulated I Cl.vol in canine atrial myocytes (Du and Sorota, 1999) and mouse ventricular myocytes (Gong et al., 2004) . Similarly, a recent report demonstrated that I Cl.vol was increased by 100 μM phenylephrine via activation of α 1 -adrenoceptor and PKC in human atrial myocytes (Li and Du, 2015) . The present study demonstrated that I Cl.vol up-regulation by noradrenaline was not affected by blocking α 1 -adrenoceptors with prazosin. A possible interpretation of this difference is that 1 μM noradrenaline may be insufficient to activate PKC in human atrial myocytes.
We found that noradrenaline and 8-pCPT-2-O-Me-cAMP were effective in augmenting I Cl.vol only under hyposmotic conditions, but failed to activate current under isosmotic conditions. The basis for dependence of I Cl.vol regulation by noradrenaline and 8-pCPT-2-O-Me-cAMP on osmotic swelling was not explored. Moreover, the goal of the present study was to determine whether Epac, an adrenergic signalling pathway of emerging importance, was critical for evoking I Cl.vol upon osmotic swelling of human atrial myocytes. Consequently, concentration-dependent effects of agonists and antagonists on the several pathways involved in the regulation of this current under isosmotic and hyposmotic conditions remain to be assessed.
On the other hand, the regulation of cardiac I Cl.vol by the β-adrenoceptor-mediated signals cAMP/PKA is also speciesdependent. Earlier studies reported that the cell swellingactivated I Cl.vol was insensitive to the PKA inhibitor H-89 in canine ventricular myocytes (Tseng, 1992) , and the positive pipette pressure-activated I Cl was not affected by PKA-specific peptide inhibitor or the protein kinase inhibitor H-7 in rabbit atrial myocytes (Hagiwara et al., 1992) . However, I Cl.vol was inhibited by the cAMP activator forskolin in cultured chick cardiac myocytes, and the current activation was prevented by inclusion of cAMP and the phosphatase inhibitor okadaic acid in the pipette solution (Hall et al., 1995) .
In contrast, the β-adrenoceptor agonist adrenaline and forskolin were demonstrated to stimulate I Cl.vol in canine atrial myocytes (Sorota, 1992) and in human atrial and ventricular myocytes (Oz and Sorota, 1995) . Nonetheless, cAMP was found to consistently inhibit, not stimulate, I Cl,vol in native guinea pig cardiac myocytes and NIH 3 T3 cells expressing recombinant gpClC3 channels (Nagasaki et al., 2000) .
It is well recognized that the β-adrenoceptor-mediated signals cAMP/PKA-activated Cl À current carried by the cystic fibrosis transmembrane conductance regulator (I Cl.CFTR ) is insensitive to inhibition by the Cl À channel blocker DIDS (Hiraoka et al., 1998; Hume et al., 2000) . It is clear that noradrenaline-stimulated I Cl.vol observed in this study is not related to I Cl.CFTR because (i) noradrenaline increased the membrane conductance at 0.6 T, but not at 1.0 T; (ii) the PKA inhibitors H-89 and PKI did not affect the current increase by noradrenaline; and (iii) DIDS significantly inhibited the current. Therefore, the noradrenaline-activated current is related to the up-regulation of I Cl.vol by a PKA-independent cAMP mechanism. cAMP also activates PKG (Schwede et al., 2000) , PI3K/PKB (Schulte and Fredholm, 2003; Shen et al., 2011) and Epac proteins (de Rooij et al., 1998; Kawasaki et al., 1998) . In the present study, the PKG inhibitor KT5823 and the PI3K/PKB inhibitor LY294002 had no effect on the stimulation of I Cl.vol by noradrenaline during cell swelling, indicating that PKG and PI3K/PKB are not involved in the response of human atrial myocytes in this setting. Interestingly, the selective Epac activator 8-pCPT-2-O-Me-cAMP mimicked the up-regulation of I Cl.vol by noradrenaline during osmotic swelling, and the Epac inhibitor ESI-09 fully reversed or prevented the I Cl.vol activation by noradrenaline. These observations support the notion that noradrenaline stimulates I Cl.vol by activating β-adrenoceptor, cAMP and thereby Epac proteins.
Epac proteins, Epac1 and Epac2, are cAMP sensors and act as guanine-nucleotide exchange factors for the small G proteins Rap1 and Rap2; the cycling of Rap between its inactive and active states provides a mechanism to regulate the effector proteins (de Rooij et al., 1998; Kawasaki et al., 1998) . Epacs are also involved in the regulation of reactive oxygen species in granulocytes (Nogueira-Machado et al., 2003) , angiotensin II-induced oxidative stress in renal tubular cells (Fang et al., 2013) and the neutrophil oxidative burst (Cerny et al., 2017) . Potentially, reactive oxygen species, which activate I Cl.vol (Browe and Baumgarten, 2004; Ren et al., 2008; Deng et al., 2010) , may play a role in the responses observed here, but the downstream target or targets of Epac responsible for augmenting I Cl.vol were not identified.
The cAMP sensors such as Epacs are at the crossroads of many physiological processes and represent potential therapeutic targets for the treatment of several cardiovascular disorders, including cardiac hypertrophy, arrhythmia and heart failure (Lezoualc'h et al., 2016) . Activation of I Cl.vol has important implications for cardiac cell volume regulation and electrical activity (Hiraoka et al., 1998; Sorota, 1999; Hume et al., 2000) . Therefore, regulation of I Cl.vol by Epac proteins mediated by β-adrenoceptor activation is expected to reflect the participation of the sympathetic neurones in modulating human cardiac physiology and pathophysiology, for example, cardiac electrophysiology and arrhythmogenesis in situ (Hiraoka et al., 1998) or cardiac hypertrophy which requires the accumulation of water as well as synthesis of proteins .
It is well established, for example, that activation of outwardly rectifying I Cl.vol substantially shortens action potential duration in cardiac myocytes while having only modest effects on resting membrane potential (Vandenberg et al., 1997; Hiraoka et al., 1998; Chiang et al., 2004) . These observations result from I Cl.vol generating larger repolarizing than depolarizing currents (i.e. outward rectifying) over the physiological voltage range. Addition of noradrenaline further augmented I Cl.vol in 0.6 T by about~31-40% at +30 mV ( Figure 1 ) and, therefore, is expected to cause additional abbreviation of the action potential. In turn, shorting of refractory periods would favour re-entry and the development of atrial tachyarrhythmias and atrial fibrillation. Nevertheless, the substrate underlying atrial dysrhythmias is complex. The importance of cAMP/Epac-induced activation of I Cl.vol and the resulting shortening of action potential duration to atrial dysrhythmia is likely to vary with the underlying pathology and with any simultaneous modulation of other ion channels by disease. One also might predict that augmentation of I Cl.vol would favour shortening of the action potential in human ventricular myocytes, but the regulation of I Cl.vol in the ventricle was not assessed here.
The present study provides novel evidence that I Cl.vol is up-regulated by cAMP/Epac proteins in human atrial myocytes during swelling. This conclusion may not be applicable in other species, because previous studies indicated that adrenergic regulation of cardiac I Cl.vol is species-dependent Duan, 2011) . A limitation of the present study is that we were unable to obtain detailed information on whether I Cl.vol channels or one of their upstream regulators interact with Epac proteins. Previous studies proposed several candidates for mediating I Cl.vol ., including the transporter P-glycoprotein, the ICln,protein phospholemman, the voltage-dependent anion channel (VDAC), the chloride channel ClC-3 and the calciumactivated chloride channel TMEM16A (Duan et al., 1997; Pedersen et al., 2015) . Recent studies have demonstrated that the protein, leucine-rich repeat containing 8A (LRRC8A, also called SWELL1) mediates I Cl.vol in the human cancer cell lines HCT166 cells and HeLa cells (Voss et al., 2014) , human CD4 + T lymphocytes and B cells (Qiu et al., 2014) , and mouse adipocyte . Functional channels are thought to result from expression of LRRC8A along with several homologous subunits in varying combinations (Gradogna et al., 2017) . Such variations may contribute to species-and tissuedependent variations in the signalling regulating this channel. More effort is required to clarify the molecular identities of I Cl.vol in human cardiac myocytes and to determine the basis for its regulation by Epacs.
In summary, the present study provides the novel information that noradrenaline up-regulates I Cl.vol activated by cell swelling via activating β-adrenoceptors, but not α-adrenoceptors. The regulation is PKA-independent and mediated by activation of the cAMP-dependent protein Epacs. Up-regulation of I Cl.vol by Epacs may contribute to abnormal cardiac electrical activity in pathological settings.
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